(Press-News.org) OKLAHOMA CITY – The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma Health Stephenson Cancer Center. The treatment offers potential hope for patients whose tumors lack a key DNA repair protein called ATM.
The drug combination pairs alnodesertib, a targeted therapy that blocks cancer cells’ ability to repair DNA damage, and a low dose of irinotecan, a chemotherapy drug that causes that damage. Together, the drugs exploit a weakness in cancer cells that are already deficient in the ATM protein.
In the trial, a substantial number of patients with ATM-deficient tumors who received the treatment experienced reductions in the size of their cancers.
“We consider this a triple hit because we target the cancer in three different ways. We target the right tumor (those with ATM deficiency) and then we attack it with two treatments that work synergistically, one that damages the DNA and the other that prevents the cancer cell from repairing the DNA and surviviving,” said Susanna Ulahannan, M.D., OU Health oncologist and associate professor in the OU College of Medicine, who was the national principal investigator for the cohort of colorectal cancer patients. “The treatment responses we have seen are very exciting, and they are in a patient group that has very few options.”
Like other forms of chemotherapy, irinotecan damages the DNA of cancer cells. Normally, a protein called ATR would try to repair that damage before the cells divide again. But alnodesertib, an ATR inhibitor, blocks the repair signal, preventing cancer cells from recovering and multiplying. This mechanism is particularly effective in cancers that already have defective repair systems, such as those lacking ATM.
The drug combination’s Fast Track Designation is for patients who have already received at least two rounds of other colorectal cancer treatments that have not been effective. Alnodesertib is from Artios Pharma Limited and was tested in the STELLA clinical trial.
According to the American Cancer Society, more than 154,000 people will be diagnosed with colorectal cancer in 2025, and 52,000 people are expected to die from the disease. The lifetime risk of developing colorectal cancer is 1 in 24 for men and 1 in 26 for women.
“We have had only two good treatment options for metastatic colorectal cancer, so there is a very high unmet need. While colorectal cancer overall is declining, it is increasing in people under 50. We are seeing young, otherwise healthy patients who have limited treatment options. This clinical trial has produced very promising results,” Ulahannan said.
###
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university with campuses in Norman, Oklahoma City and Tulsa. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. In Oklahoma City, the OU Health Campus is one of the nation’s few academic health centers with seven health profession colleges located on the same campus. The OU Health Campus serves approximately 4,000 students in more than 70 undergraduate and graduate degree programs spanning Oklahoma City and Tulsa and is the leading research institution in Oklahoma. For more information about the OU Health Campus, visit www.ouhsc.edu.
END
Research Highlights:
The cholesterol-lowering medication alirocumab, a PCSK9 inhibitor, along with a statin, lowered LDL cholesterol levels more than 50% in patients after a heart transplant, compared to those taking a placebo plus statin, according to the results of a new clinical trial.
Researchers found alirocumab did not reduce the risk of developing cardiac allograft vasculopathy, a progressive coronary artery disease that occurs after a heart transplant.
Note: This trial is simultaneously published today as a full manuscript in the peer-reviewed scientific journal Circulation.
Embargoed until 10:00 a.m. CT/11:00 a.m. ET, Monday, Nov. 10, 2025
NEW ORLEANS, Nov. ...
Research Highlights:
Among 150 adults who had been recently hospitalized for heart failure, those who received deliveries of prepared meals or fresh produce along with dietary counseling reported improved quality of life compared to adults who only received dietary guidance without food delivery.
There were no differences in the number of hospital readmissions or emergency department visits for heart failure between participants who received food delivery compared to those who did not.
Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association’s scientific meetings are not peer-reviewed, and the findings are ...
Embargoed for release until 5:00 p.m. ET on Monday 10 November 2025
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they ...
Alzheimer’s Disease (AD), the leading cause of dementia, affects nearly 40 million individuals globally, resulting in a gradual loss of memory and independence. Despite extensive research over the past decades, no treatments have been found that can halt or reverse the progression of this devastating disease.
In AD, a major contributor to neuronal dysfunction is the protein tau. Tau typically plays a crucial role in keeping the internal structure of neurons stable, much like train tracks help trains stay on course. However, in some diseases, tau undergoes abnormal modifications and ...
You are having dinner with friends, and the conversation is lively. Do your hands join the chat, or do they stay focused on your knife and fork?
New research from Duke’s Department of Psychology & Neuroscience shows that gesture is not merely a matter of individual style or habit, but a reflection of cultural expression tied to racial identity.
The research also suggests that mismatched expectations about gesture may influence the dynamics of interracial communication.
“The biggest takeaway is we all clearly communicate in very different ways,” said Gaither, Nicholas J. and Theresa M. Leonardy Associate Professor ...
When scientists compared what California sea lions eat in the Channel Islands (U.S.) and the Gulf of California (Mexico), they expected to find a clear explanation for why populations were booming in California but shrinking in Mexico. Instead, they found something more complicated.
The study found that what sea lions eat may matter less than where they live. Despite large regional differences in population trends, the study found that the overall energy value of sea lion diets in the Gulf of California ...
SAN ANTONIO, Nov. 10, 2025 – A simple blood test for platelet activity at middle age could one day help identify people at risk for Alzheimer’s disease decades ahead of time, allowing for possible preventive therapy.
The blood-clotting process in vascular dysfunction is linked to key markers of Alzheimer’s as early as midlife, a study co-led by researchers at The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, and the New York University Grossman School of Medicine shows.
Vascular dysfunction refers to a condition ...
Research Highlights:
A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received a coronary stent was as effective as one year of continuous dual therapy for preventing stroke, heart attack and death.
Participants treated with the one-month regimen experienced fewer bleeding problems than those in the year-long dual-treatment group.
This is the first study to suggest the one-month strategy is as safe and effective as the standard year-long regimen of dual clot-preventing therapy for people with AFib treated with a stent.
Note: ...
Research Highlights:
Successful catheter ablation resulted in a low risk of stroke associated with atrial fibrillation (AFib), a type of irregular heart rhythm, according to an international study.
Researchers said these findings may suggest that ongoing blood-thinning medication may not be needed after an ablation procedure.
While catheter ablation is known to reduce the occurrence of AFib, it’s been unclear if it also reduces the increased stroke risk associated with the AFib.
Note: This ...
Research Highlights:
Earlier blood transfusion after major surgery – when hemoglobin was below 10 g/dL rather than beow 7 g/dl - did not affect the risk of severe complications, such as death, heart attack, need for a heart procedure, kidney failure or stroke.
However, the timing of the blood transfusion may be associated with a lower risk of irregular heartbeat and heart failure among people with heart disease, according to a new study of U.S. military veterans.
Note: This trial is simultaneously published today as a full manuscript in the peer-reviewed scientific journal JAMA.
Embargoed ...
